Astrana Health Earnings Call Transcripts
Fiscal Year 2026
-
Strong growth and successful integration of a major acquisition have driven operational and financial outperformance, with technology and AI streamlining care and administrative processes. Regulatory changes are expected to have limited impact, and Medicaid margins are projected to recover as rate adjustments align with member acuity.
-
Q1 2026 saw 56% revenue and 82% adjusted EBITDA growth, with strong free cash flow and rapid deleveraging. Full risk contracts and AI-enabled efficiencies drove margin gains, while guidance for 2026 and 2027 remains robust amid favorable regulatory and market trends.
-
Record growth and profitability continue, with strong guidance for 2024 and 2025. Membership trends reflect industry headwinds, but efficiency, conservative risk adjustment, and AI-driven operations support resilience and margin stability.
-
A scalable delegated risk platform is driving growth through technology, full-risk contracts, and strategic acquisitions, with a focus on Medicare Advantage and operational efficiency. The model delivers strong outcomes, high retention, and positions the organization as a preferred partner amid regulatory shifts.
Fiscal Year 2025
-
Record 2025 results with 56% revenue growth, strong cash flow, and margin expansion driven by disciplined risk management, technology leverage, and successful Prospect integration. 2026 guidance reflects conservative assumptions and continued growth across markets.
-
Q3 2025 saw revenue double year-over-year and strong EBITDA growth, driven by the Prospect Health acquisition and organic expansion. Updated 2025 guidance reflects a timing delay in full-risk contracts, with margin expansion and synergy realization expected in 2026.
-
Q2 2025 saw 35% revenue growth to $654.8M and strong adjusted EBITDA, driven by full-risk contracts and Care Partners. Prospect Health acquisition closed at a lower price, improving leverage, with integration and synergy targets on track. Medicaid and exchange headwinds are seen as manageable.
-
A unique centralized network model has driven rapid, profitable growth and industry-leading efficiency, with expansion into new markets and successful acquisitions. Proprietary AI technology and a focus on full risk arrangements support continued strong financial and clinical outcomes.
-
A value-based healthcare network is expanding through the $745M Prospect Health acquisition, adding 14,000 providers and 600,000 patients, with integration supported by prior experience and robust technology. Confident in 2025 and 2027 EBITDA guidance, the company sees manageable risks in Medicare and Medicaid and expects significant growth in California.
-
Q1 2025 saw 53% revenue growth to $620.4M and strong adjusted EBITDA, driven by membership expansion and value-based care. CHS integration is complete, Prospect Health acquisition is on track, and full-year guidance remains unchanged despite sector headwinds.
-
2025 guidance projects $2.5–$2.7 billion revenue and $170–$190 million EBITDA, excluding Prospect Health, whose acquisition is expected to add $1.2 billion revenue and $81 million EBITDA. Focus is on integration, operational efficiencies, and prudent risk management, with a $350 million+ EBITDA target for 2027.
-
The event detailed a strategy to transform healthcare delivery through a pseudo-single payer model, leveraging technology and risk-bearing arrangements to drive growth, operational efficiency, and improved patient outcomes. Recent acquisitions and a focus on value-based care are expected to fuel continued expansion and profitability.
Fiscal Year 2024
-
Delivered 47% revenue growth and 16% adjusted EBITDA growth in 2024, driven by Care Partners segment expansion, value-based contract progression, and strategic acquisitions. 2025 guidance reflects continued investment, integration costs, and a focus on full risk arrangements.
-
The acquisition will expand the provider network into new markets, add 610,000 value-based care members, and is expected to generate $1.2 billion in revenue and $81 million in adjusted EBITDA for 2024. Integration will leverage proprietary technology, with $12 million in synergies targeted by 2027 and a focus on sustainable, high-quality care.
-
Q3 revenue grew 37% year-over-year to $478.7 million, with Adjusted EBITDA at $45.2 million and full-risk capitation revenue rising to 61%. The CHS acquisition expands reach and is expected to contribute $450 million in 2025 revenue, with Medicaid trends a near-term headwind.
-
Revenue grew 40% year-over-year to $486.3M, driven by organic growth and acquisitions. Full risk arrangements now comprise 60% of capitation revenue, with expansion into new states and the CHS acquisition expected to further boost scale and profitability.
-
Rapid revenue growth and strong profitability are driven by a diversified care network, proprietary technology, and a shift to full risk contracts. Expansion into new markets and accretive acquisitions support a robust outlook for continued margin and membership growth.